However, several resistance mechanisms to TKI-treatment have been documented in clinical studies, such as secondary EGFR mutations (T790M and C797S), MET amplifications, epithelial–mesenchymal transition (EMT), and particularly the activation of the Warburg effect (WE), that promotes an important metabolic remodeling in tumor cells [9,10,11]. Here, EGFR is linked to neoplasm.